Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
104.1 USD | -0.74% | -0.62% | -5.43% |
May. 15 | Abbott Laboratories Recalling HeartMate 3 Left Ventricular Assist System Implant Kit | MT |
May. 09 | Drugmaker Abbott India posts Q4 profit rise on higher sales | RE |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The company returns high margins, thereby supporting business profitability.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 30.43 times its estimated earnings per share for the ongoing year.
- The company's enterprise value to sales, at 4.47 times its current sales, is high.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-5.43% | 181B | C+ | ||
+4.30% | 114B | C | ||
-3.09% | 68.29B | A | ||
+5.86% | 52.24B | B- | ||
+8.15% | 44.3B | B- | ||
+7.52% | 42.73B | B+ | ||
+25.54% | 32.52B | B | ||
+17.85% | 26.02B | A- | ||
+1.00% | 25.91B | A- | ||
-1.25% | 24.72B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ABT Stock
- Ratings Abbott Laboratories